These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 8149945)
1. Kinetics of propiverine as assessed by radioreceptor assay in poor and extensive metabolizers of debrisoquine. Müller C; Siegmund W; Huupponen R; Kaila T; Franke G; Iisalo E; Zschiesche M Eur J Drug Metab Pharmacokinet; 1993; 18(3):265-72. PubMed ID: 8149945 [TBL] [Abstract][Full Text] [Related]
2. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation. Meier PJ; Mueller HK; Dick B; Meyer UA Gastroenterology; 1983 Sep; 85(3):682-92. PubMed ID: 6603386 [TBL] [Abstract][Full Text] [Related]
3. Polymorphic ochratoxin A hydroxylation in rat strains phenotyped as poor and extensive metabolizers of debrisoquine. Castegnaro M; Bartsch H; Bereziat JC; Arvela P; Michelon J; Broussolle L Xenobiotica; 1989 Feb; 19(2):225-30. PubMed ID: 2786290 [TBL] [Abstract][Full Text] [Related]
4. The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers. Philip PA; James CA; Rogers HJ Eur J Clin Pharmacol; 1989; 36(3):319-21. PubMed ID: 2744073 [TBL] [Abstract][Full Text] [Related]
5. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826 [TBL] [Abstract][Full Text] [Related]
6. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Llerena A; Edman G; Cobaleda J; Benítez J; Schalling D; Bertilsson L Acta Psychiatr Scand; 1993 Jan; 87(1):23-8. PubMed ID: 8424321 [TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. Llerena A; Dorado P; Peñas-Lledó EM Pharmacogenomics; 2009 Jan; 10(1):17-28. PubMed ID: 19102711 [TBL] [Abstract][Full Text] [Related]
10. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio. Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748 [TBL] [Abstract][Full Text] [Related]
12. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship. Dorado P; Berecz R; Cáceres MC; González I; Cobaleda J; Llerena A Clin Chem Lab Med; 2005; 43(3):275-9. PubMed ID: 15843230 [TBL] [Abstract][Full Text] [Related]
13. Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation. Danhof M; Idle JR; Teunissen MW; Sloan TP; Breimer DD; Smith RL Pharmacology; 1981; 22(6):349-58. PubMed ID: 7267701 [TBL] [Abstract][Full Text] [Related]
14. Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine. Leclercq V; Desager JP; Horsmans Y; Van Nieuwenhuyze Y; Harvengt C Int J Clin Pharmacol Ther Toxicol; 1989 Dec; 27(12):593-8. PubMed ID: 2613393 [TBL] [Abstract][Full Text] [Related]
15. Debrisoquine oxidation in Parkinson's disease. Kallio J; Marttila RJ; Rinne UK; Sonninen V; Syvälahti E Acta Neurol Scand; 1991 Mar; 83(3):194-7. PubMed ID: 2031454 [TBL] [Abstract][Full Text] [Related]
17. Maprotiline metabolism appears to co-segregate with the genetically-determined CYP2D6 polymorphic hydroxylation of debrisoquine. Firkusny L; Gleiter CH Br J Clin Pharmacol; 1994 Apr; 37(4):383-8. PubMed ID: 8018460 [TBL] [Abstract][Full Text] [Related]
18. N-acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert's syndrome. Siegmund W; Fengler JD; Franke G; Zschiesche M; Eike O; Eike E; Meisel P; Wulkow R Br J Clin Pharmacol; 1991 Oct; 32(4):467-72. PubMed ID: 1958441 [TBL] [Abstract][Full Text] [Related]
19. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439 [TBL] [Abstract][Full Text] [Related]
20. CYP2D6 polymorphism is not crucial for the disposition of selegiline. Scheinin H; Anttila M; Dahl ML; Karnani H; Nyman L; Taavitsainen P; Pelkonen O; Bertilsson L Clin Pharmacol Ther; 1998 Oct; 64(4):402-11. PubMed ID: 9797797 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]